Where AI is bringing real value to R&D_A

Where AI is bringing real value to pharma R&D

AI is emerging as a catalyst for breakthroughs in biopharma R&D – streamlining discovery, optimising trial design, and enabling predictive insights – and it’s now poised to bring biopharma R&D more agile, data-driven, and outcome-oriented processes.Contents

Thank you for reading

Where AI is bringing real value to R&D

The state of play

AI is emerging as a powerful catalyst for R&D breakthroughs precisely in the areas where the industry has struggled most in recent years.

Our global survey of 500 senior biopharma execs reveals that 82% believe AI will fundamentally transform R&D.

They report that AI is already delivering value in some parts of the R&D value chain…

Where execs see potential for different forms of AI in the R&D value chain

Source: Capgemini Research Institute, Impact of AI on R&D productivity survey, August–September 2025, N=478 pharmaceutical and biotechnology executives.
*CMC: Chemistry, manufacturing, and controls.

Most organizations are exploring or piloting AI agents in R&D

Source: Capgemini Research Institute, Impact of AI on R&D productivity survey, August–September 2025, N=500 pharmaceutical and biotechnology executives.

Top AI investments in each R&D segment

Source: Capgemini Research Institute, Impact of AI on R&D productivity survey, August–September 2025, N=500 pharmaceutical and biotechnology executives.

There is more detail for each segment in the full report

Value already delivered

Target identification

28%

time savings on average

Biomarker identification

22%

time savings on average

Compound
screening

20%

time savings on average

Preparation for
regulatory submission

19%

time savings on average

Source: Capgemini Research Institute, Impact of AI on R&D productivity survey, August–September 2025, N=500 pharmaceutical and biotechnology executives.

In the full report…

Laying the groundwork for big bets on AI in R&D
How AI is reshaping parts of the R&D value chain today
Barriers to biopharma realizing AI’s potential
How biopharma organizations can accelerate and scale AI in R&D